
New Stock Debut | Multiple Hong Kong stocks listed today, INSILICO opened 45% higher in early trading

Multiple Hong Kong stock targets listed today, INSILICO opened 45% higher in the morning, ONEROBOTICS opened flat in the morning, 51WORLD opened 14% higher in the morning, FOREST CABIN opened 9% higher in the morning, and USAS BUILDING opened 15% higher in the morning
On December 30th (Tuesday), several Hong Kong stock targets were listed today. INSILICO opened 45% higher in the morning, ONEROBOTICS opened flat, 51WORLD opened 14% higher, FOREST CABIN opened 9% higher, and USAS BUILDING opened 15% higher.
In terms of news:
USAS BUILDING
USAS BUILDING is a comprehensive service provider in the field of prefabricated steel structure construction in China, mainly providing integrated services such as design optimization, procurement, manufacturing, and installation for various construction projects. The company's business is primarily focused on China, with expansion into overseas markets. Relying on technology and expertise, it has established a good reputation in the industrial prefabricated steel structure field.
FOREST CABIN
FOREST CABIN is a high-end domestic skincare brand in China, focusing on the anti-wrinkle and firming skincare market, with natural camellia flower ingredients at its core, providing high-end skincare solutions. Since 2012, the brand has pioneered the concept of "nourishing the skin with oil" and launched its first camellia essence oil in 2014, establishing its core product line. As of June 30, 2025, this product has sold over 45 million bottles. According to statistics from ZhiShi Consulting, its omni-channel retail sales have ranked first in the national facial essence oil category for 11 consecutive years and is the only facial essence oil product to have exceeded RMB 100 million in retail sales for 8 consecutive years.
51WORLD
51WORLD is a Chinese digital twin technology company that has built complete technical capabilities on three components of Physical AI: data fuel, spatial models, and training platforms, forming a full-chain closed-loop ecosystem of "synthetic data - spatial intelligent models - simulation training platforms," establishing technical and ecological barriers, and becoming one of the few companies globally with the three elements of Physical AI.
The company has launched three core businesses: the 51Aes digital twin platform, the 51Sim synthetic data and simulation platform, and the 51Earth digital earth platform, serving over a thousand large and medium-sized enterprises globally, covering 19 countries and regions, and achieving commercialization in various scenarios such as intelligent driving, smart factories, and smart energy.
ONEROBOTICS
ONEROBOTICS is a global provider of home robot systems aimed at the Japanese, European, and North American markets, dedicated to building a smart home robot ecosystem. According to a Frost & Sullivan report, based on retail sales in 2024, the company ranks first among global home robot system providers with a market share of 11.9%.
The company focuses on developing robot systems that cover diverse home scenarios, with products mainly including enhanced execution robots and perception and decision-making systems. Among them, flexible skill robots can simulate human hand movements to perform functions such as controlling door locks and curtains; enhanced mobile robots simulate foot movements and achieve composite functions such as cleaning, delivery, monitoring, and even sports interaction through modular combinations.
INSILICO
INSILICO is a global leader in AI-driven drug development. Its self-developed generative artificial intelligence platform Pharma.AI integrates four major modules: Biology42, Chemistry42, Medicine42, and Science42, covering the entire process from target identification to clinical prediction. The company promotes drug development through various models, including self-development and collaborative licensing As of the latest feasible date, the company has generated over 20 clinical or IND application stage assets relying on the Pharma.AI platform, among which three have been licensed to international pharmaceutical companies, with a potential total contract value of up to $2.1 billion, and possesses a self-developed Phase II asset, with R&D progress at the forefront of the industry
